Treatment of JIA is categorized into non-biological treatments (anti-inflammatory drugs, corticosteroids, and disease-modifying antirheumatic drugs such as methotrexate, sulfasalazine, and leflunomide) and biological therapies, which target specific proinflammatory cytokines involved in JIA pathogenesis, such as interleukin (IL)-1, IL-6, and tumor necrosis factor [3]. This evidence concerns the gene TNF and juvenile idiopathic arthritis.